Skip to main content

Advertisement

SpringerLink
Log in

Treatment of chronic myeloid leukemia with imatinib mesylate

  • REVIEW ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL, c-Kit and PGDF-receptor, and functions through competitive inhibition at the ATP-binding site of the enzyme, which leads to growth arrest or apoptosis in cells that express BCR-ABL. Imatinib has revolutionized the management of patients with CML, and at a dose of 400 mg daily has become the current standard therapy for newly diagnosed patients with CML even when they have HLA-matched family donors. Although imatinib therapy has only a 5-year history, it is hoped that CML will be cured with this drug and with forthcoming second-generation tyrosine kinase inhibitors as well as by allogeneic stem cell transplantation in patients who have become resistant to these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. PC Nowell DA Hungerford (1960) ArticleTitleA minute chromosome in human granulocytic leukemia Science 132 1497–1497

    Google Scholar 

  2. JD Rowley (1973) ArticleTitleA new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290–293 Occurrence Handle4126434 Occurrence Handle1:STN:280:CSuD3cnjslU%3D Occurrence Handle10.1038/243290a0

    Article  PubMed  CAS  Google Scholar 

  3. S Faderl M Talpaz Z Estrov et al. (1999) ArticleTitleThe biology of chronic myeloid leukemia N Engl J Med 341 164–172 Occurrence Handle10403855 Occurrence Handle1:CAS:528:DyaK1MXkslCktrc%3D Occurrence Handle10.1056/NEJM199907153410306

    Article  PubMed  CAS  Google Scholar 

  4. CL Sawyers (1999) ArticleTitleChronic myeloid leukemia N Engl J Med 340 1330–1340 Occurrence Handle10219069 Occurrence Handle1:STN:280:DyaK1M3hvFOlug%3D%3D Occurrence Handle10.1056/NEJM199904293401706

    Article  PubMed  CAS  Google Scholar 

  5. MW Deininger JM Goldman JV Melo (2000) ArticleTitleThe molecular biology of chronic myeloid leukemia Blood 96 3343–3356 Occurrence Handle11071626 Occurrence Handle1:CAS:528:DC%2BD3cXotFKktb8%3D

    PubMed  CAS  Google Scholar 

  6. GQ Daley RA Van Etten D Baltimore (1990) ArticleTitleInduction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome Science 247 824–830 Occurrence Handle2406902 Occurrence Handle1:CAS:528:DyaK3cXhsFaqs7c%3D

    PubMed  CAS  Google Scholar 

  7. TG Lugo AM Pendergast AJ Muller et al. (1990) ArticleTitleTyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 247 1079–1082 Occurrence Handle2408149 Occurrence Handle1:CAS:528:DyaK3cXhslensbg%3D

    PubMed  CAS  Google Scholar 

  8. J Cortes (2004) ArticleTitleNatural history and staging of chronic myelogenous leukemia Hematol Oncol Clin North Am 18 569–584 Occurrence Handle15271393 Occurrence Handle10.1016/j.hoc.2004.03.011

    Article  PubMed  Google Scholar 

  9. G Garcia-Manero S Fader S O'Brien (2003) ArticleTitleChronic myelogenous leukemia: a review and update of therapeutic strategies Cancer 98 427–456 Occurrence Handle10.1002/cncr.11520

    Article  Google Scholar 

  10. R Hehlmann U Berger A Hochhaus (2005) ArticleTitleChronic myeloid leukemia: a model for oncology Ann Hematol 84 487–497 Occurrence Handle15931535 Occurrence Handle10.1007/s00277-005-1039-z

    Article  PubMed  Google Scholar 

  11. R Hehlmann U Berger M Pfirrmann et al. (2003) ArticleTitleRandomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): prolongation of survival by the combination of interferon α and hydroxyurea Leukemia 17 1529–1537 Occurrence Handle12886239 Occurrence Handle1:CAS:528:DC%2BD3sXlslOitr8%3D Occurrence Handle10.1038/sj.leu.2403006

    Article  PubMed  CAS  Google Scholar 

  12. HM Kantarjian T Smith S O'Brien et al. (1995) ArticleTitleProlonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy Ann Intern Med 122 254–261 Occurrence Handle7825760 Occurrence Handle1:STN:280:ByqC38njtVE%3D

    PubMed  CAS  Google Scholar 

  13. K Ohnishi R Ohno M Tomonaga et al. (1995) ArticleTitleA randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase Blood 86 906–916 Occurrence Handle7620184 Occurrence Handle1:CAS:528:DyaK2MXnt1Srurs%3D

    PubMed  CAS  Google Scholar 

  14. K Ohnishi S Minami T Ueda et al. (2000) ArticleTitleMulticenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia Int J Hematol 72 229–236 Occurrence Handle11039674 Occurrence Handle1:CAS:528:DC%2BD3cXns1Cqsbg%3D

    PubMed  CAS  Google Scholar 

  15. RP Gale R Hehlmann M-J Zhang et al. (1998) ArticleTitleSurvival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia Blood 91 1810–1819 Occurrence Handle9473250 Occurrence Handle1:CAS:528:DyaK1cXht12gt7k%3D

    PubMed  CAS  Google Scholar 

  16. JA Hansen TA Gooley PJ Martin et al. (1998) ArticleTitleBone marrow transplants from unrelated donors for patients with chronic myeloid leukemia N Engl J Med 338 962–968 Occurrence Handle9521984 Occurrence Handle1:STN:280:DyaK1c7nt12muw%3D%3D Occurrence Handle10.1056/NEJM199804023381405

    Article  PubMed  CAS  Google Scholar 

  17. ME Gorre M Mohammed K Ellwood et al. (2002) ArticleTitleCurrent trends in hematopoietic stem cell transplantation in Europe Blood 100 2374–2386 Occurrence Handle10.1182/blood-2002-05-1361

    Article  Google Scholar 

  18. BJ Druker S Tamura E Buchdunger et al. (1996) ArticleTitleEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561–566 Occurrence Handle8616716 Occurrence Handle1:CAS:528:DyaK28Xislyhs70%3D Occurrence Handle10.1038/nm0596-561

    Article  PubMed  CAS  Google Scholar 

  19. M Deininger E Buchdunger BJ Druker (2005) ArticleTitleThe development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2640–2653 Occurrence Handle15618470 Occurrence Handle1:CAS:528:DC%2BD2MXivFGmsb0%3D Occurrence Handle10.1182/blood-2004-08-3097

    Article  PubMed  CAS  Google Scholar 

  20. BJ Druker M Talpaz DJ Resta et al. (2001) ArticleTitleEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031–1037 Occurrence Handle11287972 Occurrence Handle1:CAS:528:DC%2BD3MXivFGnu70%3D Occurrence Handle10.1056/NEJM200104053441401

    Article  PubMed  CAS  Google Scholar 

  21. B Peng M Hayes D Resta et al. (2004) ArticleTitlePharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 935–942 Occurrence Handle14990650 Occurrence Handle1:CAS:528:DC%2BD2cXpsVKisrY%3D Occurrence Handle10.1200/JCO.2004.03.050

    Article  PubMed  CAS  Google Scholar 

  22. BJ Druker CL Sawyers H Kantarjian et al. (2001) ArticleTitleActivity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 1038–1042 Occurrence Handle11287973 Occurrence Handle1:CAS:528:DC%2BD3MXivFGnu7o%3D Occurrence Handle10.1056/NEJM200104053441402

    Article  PubMed  CAS  Google Scholar 

  23. H Kantarjian C Sawyers A Hochhaus et al. (2002) ArticleTitleHematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645–652 Occurrence Handle11870241 Occurrence Handle1:CAS:528:DC%2BD38XhsFOjsr8%3D Occurrence Handle10.1056/NEJMoa011573

    Article  PubMed  CAS  Google Scholar 

  24. M Talpaz RT Silver BJ Druker et al. (2002) ArticleTitleImatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study Blood 99 1928–1937 Occurrence Handle11877262 Occurrence Handle1:CAS:528:DC%2BD38XitF2nt74%3D Occurrence Handle10.1182/blood.V99.6.1928

    Article  PubMed  CAS  Google Scholar 

  25. CL Sawyers A Hochhaus E Feldman et al. (2002) ArticleTitleImatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study Blood 99 3530–3539 Occurrence Handle11986204 Occurrence Handle1:CAS:528:DC%2BD38XjvVGns78%3D Occurrence Handle10.1182/blood.V99.10.3530

    Article  PubMed  CAS  Google Scholar 

  26. OG Ottmann BJ Druker CL Sawyers et al. (2002) ArticleTitleA phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Blood 100 1965–1971 Occurrence Handle12200353 Occurrence Handle1:CAS:528:DC%2BD38Xnt1yiu7Y%3D Occurrence Handle10.1182/blood-2001-12-0181

    Article  PubMed  CAS  Google Scholar 

  27. M Towatari M Yanada N Usui et al. (2004) ArticleTitleCombination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood 104 3507–3512 Occurrence Handle15315963 Occurrence Handle1:CAS:528:DC%2BD2cXhtVGltLfF Occurrence Handle10.1182/blood-2004-04-1389

    Article  PubMed  CAS  Google Scholar 

  28. M Yanada J Takeuchi I Sugiura et al. (2006) ArticleTitleHigh complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 460–466 Occurrence Handle16344315 Occurrence Handle1:CAS:528:DC%2BD28XhsFSku7c%3D Occurrence Handle10.1200/JCO.2005.03.2177

    Article  PubMed  CAS  Google Scholar 

  29. Y Morishima M Ogura M Nishimura et al. (2004) ArticleTitleEfficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study Int J Hematol 80 261–266 Occurrence Handle15540902 Occurrence Handle1:CAS:528:DC%2BD2cXhtVShtLvK Occurrence Handle10.1532/IJH97.04074

    Article  PubMed  CAS  Google Scholar 

  30. SG O'Brien F Guilhot RA Larson et al. (2003) ArticleTitleImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994–1004 Occurrence Handle12637609 Occurrence Handle10.1056/NEJMoa022457

    Article  PubMed  Google Scholar 

  31. F Guilhot C Chastang M Michallet et al. (1997) ArticleTitleInterferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia N Engl J Med 337 223–229 Occurrence Handle9227927 Occurrence Handle1:CAS:528:DyaK2sXltlSktLc%3D Occurrence Handle10.1056/NEJM199707243370402

    Article  PubMed  CAS  Google Scholar 

  32. TP Hughes J Kaeda S Branford et al. (2003) ArticleTitleFrequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423–1432 Occurrence Handle14534335 Occurrence Handle1:CAS:528:DC%2BD3sXotVGgs7s%3D Occurrence Handle10.1056/NEJMoa030513

    Article  PubMed  CAS  Google Scholar 

  33. EA Hahn GA Glendenning MV Sorensen et al. (2003) ArticleTitleQuality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alpha plus low-dose cytarabine: results from the IRIS Study J Clin Oncol 21 2138–2146 Occurrence Handle12775739 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGqtbY%3D Occurrence Handle10.1200/JCO.2003.12.154

    Article  PubMed  CAS  Google Scholar 

  34. InstitutionalAuthorNameSimonsson B on behalf of the IRIS (International Randomized IFN vs STI571) Study Group (2005) ArticleTitleBeneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): Update from the IRIS Study Blood 106 52a

    Google Scholar 

  35. HM Kantarjian S O'Brien J Cortes et al. (2003) ArticleTitleImatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase: comparison with historic data Cancer 98 2636–2642 Occurrence Handle14669283 Occurrence Handle1:CAS:528:DC%2BD2cXit1yhtw%3D%3D Occurrence Handle10.1002/cncr.11831

    Article  PubMed  CAS  Google Scholar 

  36. Shah NP (2005) Chronic myeloid leukemia; Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program):183–187

  37. ME Gorre M Mohammed K Ellwood et al. (2001) ArticleTitleClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876–880 Occurrence Handle11423618 Occurrence Handle1:CAS:528:DC%2BD3MXlvVKrsbs%3D Occurrence Handle10.1126/science.1062538

    Article  PubMed  CAS  Google Scholar 

  38. N von Bubnoff F Schneller C Peschel J Duyster (2002) ArticleTitleBCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 359 487–491 Occurrence Handle11853795 Occurrence Handle1:CAS:528:DC%2BD38Xhtlekt74%3D Occurrence Handle10.1016/S0140-6736(02)07679-1

    Article  PubMed  CAS  Google Scholar 

  39. S Branford Z Rudzki S Walsh et al. (2002) ArticleTitleHigh frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 3472–3475 Occurrence Handle11964322 Occurrence Handle1:CAS:528:DC%2BD38XjtlGqtrk%3D Occurrence Handle10.1182/blood.V99.9.3472

    Article  PubMed  CAS  Google Scholar 

  40. WK Hofmann S de Vos D Elashoff et al. (2002) ArticleTitleRelation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 359 481–486 Occurrence Handle11853794 Occurrence Handle1:CAS:528:DC%2BD38Xhtlektrc%3D Occurrence Handle10.1016/S0140-6736(02)07678-X

    Article  PubMed  CAS  Google Scholar 

  41. C Roche-Lestienne V Soenen-Cornu N Grardel-Duflos et al. (2002) ArticleTitleSeveral types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 1014–1018 Occurrence Handle12130516 Occurrence Handle1:CAS:528:DC%2BD38XlvVCltbY%3D Occurrence Handle10.1182/blood.V100.3.1014

    Article  PubMed  CAS  Google Scholar 

  42. NP Shah JM Nicoll B Nagar et al. (2002) ArticleTitleMultiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 117–125 Occurrence Handle12204532 Occurrence Handle1:CAS:528:DC%2BD38XmslSks7c%3D Occurrence Handle10.1016/S1535-6108(02)00096-X

    Article  PubMed  CAS  Google Scholar 

  43. A Hochhaus S Kreil AS Corbin et al. (2002) ArticleTitleMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2190–2196 Occurrence Handle12399961 Occurrence Handle1:CAS:528:DC%2BD38XotFWktrk%3D Occurrence Handle10.1038/sj.leu.2402741

    Article  PubMed  CAS  Google Scholar 

  44. AS Corbin PL Rosee EP Stoffregen et al. (2003) ArticleTitleSeveral Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood 101 4611–4614 Occurrence Handle12576318 Occurrence Handle1:CAS:528:DC%2BD3sXktFKgsro%3D Occurrence Handle10.1182/blood-2002-12-3659

    Article  PubMed  CAS  Google Scholar 

  45. HM Kantarjian M Talpaz S O'Brien et al. (2003) ArticleTitleDose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Blood 101 473–475 Occurrence Handle12393385 Occurrence Handle1:CAS:528:DC%2BD3sXkvVWksQ%3D%3D Occurrence Handle10.1182/blood-2002-05-1451

    Article  PubMed  CAS  Google Scholar 

  46. J Cortes F Giles S O'Brien et al. (2003) ArticleTitleResult of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α Blood 102 83–86 Occurrence Handle12637317 Occurrence Handle1:CAS:528:DC%2BD3sXltFemtb8%3D Occurrence Handle10.1182/blood-2003-01-0025

    Article  PubMed  CAS  Google Scholar 

  47. NP Shah C Tran FY Lee et al. (2004) ArticleTitleOverriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399–401 Occurrence Handle15256671 Occurrence Handle1:CAS:528:DC%2BD2cXls1egtrY%3D Occurrence Handle10.1126/science.1099480

    Article  PubMed  CAS  Google Scholar 

  48. T O'Hare DK Walters EP Stoffregen et al. (2005) ArticleTitleIn vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 4500–4505 Occurrence Handle15930265 Occurrence Handle10.1158/0008-5472.CAN-05-0259

    Article  PubMed  Google Scholar 

  49. E Weisberg PW Manley W Breitenstein et al. (2005) ArticleTitleCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129–141 Occurrence Handle15710326 Occurrence Handle1:CAS:528:DC%2BD2MXitFygu7o%3D Occurrence Handle10.1016/j.ccr.2005.01.007

    Article  PubMed  CAS  Google Scholar 

  50. S Kimura H Naito H Segawa et al. (2005) ArticleTitleNS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 3948–3954 Occurrence Handle16105974 Occurrence Handle1:CAS:528:DC%2BD2MXht12ktrzL Occurrence Handle10.1182/blood-2005-06-2209

    Article  PubMed  CAS  Google Scholar 

  51. T Lange DW Niederwieser MW Deininger (2003) ArticleTitleResidual disease in chronic myeloid leukemia after induction of molecular remission N Engl J Med 349 1483–1484 Occurrence Handle14534349 Occurrence Handle1:CAS:528:DC%2BD3sXotVGgt70%3D Occurrence Handle10.1056/NEJM200310093491521

    Article  PubMed  CAS  Google Scholar 

  52. J Cortes S O'Brien H Kantarjian (2004) ArticleTitleDiscontinuation of imatinib therapy after achieving a molecular response Blood 104 2204–2205 Occurrence Handle15377577 Occurrence Handle1:CAS:528:DC%2BD2cXotVyjsrs%3D Occurrence Handle10.1182/blood-2004-04-1335

    Article  PubMed  CAS  Google Scholar 

  53. JP Radich G Gehly T Gooley et al. (1995) ArticleTitlePolymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients Blood 85 2632–2638 Occurrence Handle7727789 Occurrence Handle1:CAS:528:DyaK2MXlt1OlsLw%3D

    PubMed  CAS  Google Scholar 

  54. Deininger MWN (2005) Chronic myeloid leukemia: management of early stage disease. Hematology (Am Soc Hematol Educ Program):174–182

  55. JJ Molldrem PP Lee C Wang et al. (2000) ArticleTitleEvidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat Med 6 1018–1023 Occurrence Handle10973322 Occurrence Handle1:CAS:528:DC%2BD3cXmslSjuro%3D Occurrence Handle10.1038/79526

    Article  PubMed  CAS  Google Scholar 

  56. A Burchert S Wolfl M Schmidt et al. (2003) ArticleTitleInterferon alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia Blood 101 259–264 Occurrence Handle12393722 Occurrence Handle1:CAS:528:DC%2BD3sXhtFWhsw%3D%3D Occurrence Handle10.1182/blood-2002-02-0659

    Article  PubMed  CAS  Google Scholar 

  57. OA Elisseeva Y Oka A Tsuboi et al. (2002) ArticleTitleHumoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood 99 3272–3279 Occurrence Handle11964293 Occurrence Handle1:CAS:528:DC%2BD38XjtlGqs7Y%3D Occurrence Handle10.1182/blood.V99.9.3272

    Article  PubMed  CAS  Google Scholar 

  58. Y Kano M Akutsu S Tsunoda et al. (2001) ArticleTitleIn vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 1999–2007 Occurrence Handle11264164 Occurrence Handle1:CAS:528:DC%2BD3MXjvFCqsro%3D Occurrence Handle10.1182/blood.V97.7.1999

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aichi Cancer Center and Aichi Syukutoku University, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan

    Ryuzo Ohno

Authors
  1. Ryuzo Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuzo Ohno.

About this article

Cite this article

Ohno, R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol 11, 176–183 (2006). https://doi.org/10.1007/s10147-006-0582-5

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-006-0582-5

Key words

Search

Navigation